All of the top performers in August were the stocks focusing on large buybacks with relatively small dividends.
Anatomy of a Biotech Trade: Transcept Pharmaceuticals
In most biotech life cycles, there are always several defining moments that could make or break their valuations
Behind investors' current love affair with fixed income assets
Investors poured $30 billion into taxable-bond funds and another $5.6 billion into municipal-bond funds in August.
Rising oil demand may benefit some MLPs
The world still has a growing thirst for oil amid the continued worries of an economic slowdown. That may benefit some oil and gas MLPs.
Why stability and performance are this model's core aims
Being “stable” means not running with the bulls or the bears.
Our model is ready for the lower market volatility ahead
As we head into the fall, our models indicate the currently lower volatility will likely stay for a period of time.
Quality tech stocks appear poised for a nice run
I believe we are nearing the point where the tech sector will rise again as it did in the late nineties.
The stocks driving our Long Term GARP model's performance
As the portfolio is full of powerful companies, there are always things happening which are eventful.
Survival of the fittest is what this portfolio is all about
The portfolio might better be called the Stock Market Darwinism model as I seek only top dogs for inclusion.
A primer on efficient frontier portfolio management
Here's a way to build portfolios that could maximize an investor's return for a given risk level.